Free Trial

Organovo Q1 2025 Earnings Report

Organovo logo
$0.38 0.00 (-0.78%)
As of 01/21/2025 04:00 PM Eastern

Organovo EPS Results

Actual EPS
-$0.23
Consensus EPS
-$0.38
Beat/Miss
Beat by +$0.15
One Year Ago EPS
N/A

Organovo Revenue Results

Actual Revenue
$0.04 million
Expected Revenue
$0.03 million
Beat/Miss
Beat by +$10.00 thousand
YoY Revenue Growth
N/A

Organovo Announcement Details

Quarter
Q1 2025
Time
N/A

Conference Call Resources

Organovo Earnings Headlines

Organovo (NASDAQ:ONVO) Research Coverage Started at StockNews.com
Organovo Appoints Norman Staskey As CFO
Please take this warning seriously...
I’m here to issue a stark warning to you about an unexpected $2 trillion shock that could impact every trader in the country – in the next 30 days. In fact, I believe it could begin as soon as January 29th… Meaning you don’t have much time to prepare.
See More Organovo Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Organovo? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Organovo and other key companies, straight to your email.

About Organovo

Organovo (NASDAQ:ONVO), a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company offers ExVive 3D bioprinted human liver tissue with distinct hepatocellular and non-parenchymal cell compartments. The company was incorporated in 2007 and is headquartered in San Diego, California.

View Organovo Profile

More Earnings Resources from MarketBeat